Elios Therapeutics announced positive top-line results from the prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial evaluating its lead immuno-oncology candidate, TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine, in patients with stage 3 and 4 resected melanoma.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
